Where Should Healthtech Companies Grow Next? A TAM / SAM / SOM Approach

Direct answer: For a healthtech or digital health company deciding where to grow next, TAM / SAM / SOM forces you to separate the whole addressable market (TAM) from the slice you can actually sell to given your regulatory clearances, payer contracts, and channel (SAM), and from the realistic share you can capture in 12–24 months (SOM). The right next move is usually the adjacent segment where your existing clinical evidence, reimbursement pathway, or integration footprint carries over — not the biggest number on the slide.

This matters more in healthtech than almost anywhere else, because the "market" you can technically reach is heavily gated by FDA clearance status, HIPAA and data-residency constraints, payer coverage, and whether a health system will actually integrate you into their EHR. A large TAM that ignores those gates is a fundraising number, not a growth plan.

Why the standard TAM / SAM / SOM breaks in digital health

In most SaaS, SAM is a filter on geography and company size. In healthtech, the SAM filter is a stack of access gates that either exist or don't:

• Regulatory: Are you selling a wellness tool, a Class I/II device, or a regulated SaMD? Each opens a different market and closes others.
• Reimbursement: Is there a CPT code, an RPM/RTM pathway, a value-based contract, or are you cash-pay/employer-paid? This single question can 10x or 0.1x your reachable market.
• Buyer and channel: Provider (health system), payer, employer, pharma, or direct-to-consumer. Each has a different sales motion and a different addressable population.
• Integration: Can you actually get into Epic/Cerner, or a specific EHR ecosystem, without a multi-quarter build?

Growth decisions fail when teams treat these as marketing details instead of what they are: the walls that define your real market. TAM / SAM / SOM done well makes the walls visible.

A concrete walkthrough for a healthtech company

Say you sell a remote patient monitoring (RPM) platform for cardiology, currently reimbursed under RPM CPT codes, sold to mid-size cardiology groups.

Step 1 — Define TAM honestly. TAM is the total annual revenue if every patient/provider who could clinically benefit used a product like yours. Build it bottom-up: number of relevant patients or providers × plausible annual contract value. Avoid top-down "$X billion digital health market" numbers — they're unciteable and hide the gates.

Good looks like: TAM built from a named population (e.g., cardiology patients eligible for RPM) times a defensible per-unit revenue figure you can source.

Step 2 — Cut to SAM using your gates. From TAM, subtract everything you can't currently serve:

• Segments with no reimbursement pathway you qualify for.
• Geographies where you lack licensure or data-residency compliance.
• Buyers who require an integration you don't have.
• Clinical indications outside your clearance or evidence base.

For the RPM example, SAM might be cardiology and adjacent chronic-condition groups in states where your billing model works and where you already integrate.

Step 3 — Size SOM realistically. SOM is what you can win in the next 12–24 months given your sales capacity, evidence, and competitive density. Anchor it to: current win rate, sales cycle length, reference customers, and how contested each segment is. If a segment is dominated by an incumbent with signed payer contracts, your SOM there is small regardless of SAM.

Step 4 — Compare growth vectors. Now the actual decision. Score each candidate move — new indication, new buyer type (e.g., payer instead of provider), new geography — on: evidence carryover, reimbursement carryover, integration carryover, and competitive whitespace. The best "grow next" is the vector with the highest carryover and the least contested SOM. Often that's an adjacent clinical indication using the same billing pathway — boring, and correct.

How Percision helps — and when it's overkill

Full disclosure: I write for Percision, a strategic intelligence platform, so weigh this accordingly.

Percision runs your business context through structured reasoning steps across multiple frameworks — TAM / SAM / SOM among 27+ — and produces board-ready output in minutes rather than the weeks a manual market-sizing exercise usually takes. For a healthtech growth decision, that's useful in three specific ways:

1. Structured segmentation across multiple vectors at once — comparing "new indication" vs. "new payer channel" vs. "new geography" on consistent criteria instead of ad hoc.
2. Financial translation — turning a chosen SOM into a DCF-informed view and an Excel-exportable model with an audit trail your board and finance team can interrogate.
3. Execution scaffolding — converting the sizing into a scenario analysis and KPI dashboard so "grow into payer contracts" becomes a tracked plan, not a slide.

It's built as a co-pilot, not an autopilot: it structures and pressure-tests the analysis, but your clinical, regulatory, and commercial leaders own the inputs and the call. Broader AI-productivity research (e.g., the 2023 BCG–Harvard field study on knowledge work) points to meaningful speed gains from AI on structured analytical tasks — a directional finding, not a promise about your specific market.

When you don't need it: If you're weighing one obvious adjacent segment and already have the reimbursement and integration facts, a spreadsheet and a two-hour session with your commercial and regulatory leads is enough. And when the core uncertainty is clinical or regulatory — will this indication get coverage, will this study read out — a specialist healthtech consultant or regulatory advisor is the right spend, not a strategy platform. Percision sizes and prioritizes markets; it doesn't run your clinical trial or negotiate your payer contract.

FAQ

Is our TAM the "digital health market" figure from an analyst report? No. Those top-down numbers aren't defensible for a growth decision. Build TAM bottom-up from the specific patient or provider population you clinically serve times a per-unit revenue figure you can source.

Should healthtech companies grow by indication or by geography first? Usually by adjacent indication that reuses your existing reimbursement pathway and integrations — carryover beats raw market size. Geography adds licensure and data-residency gates that can shrink your real SAM fast.

How fast can we run this analysis? A focused manual pass takes days if your regulatory and reimbursement facts are ready. Percision produces a board-ready version in roughly 7–15 minutes once your context is entered — see percision.app — but the human review of the gates still matters most.

Disclosure: This article was produced by Percision's content team. Percision is one option for running this analysis, not the only one.